| Autor: |
Laffel, Lori M, Danne, Thomas, Klingensmith, Georgeanna J, Tamborlane, William V, Willi, Steven, Zeitler, Philip, Neubacher, Dietmar, Marquard, Jan, Bardymova, Tatiana, Barrientos Perez, Margarita, Bethin, Kathleen, Bjornstad, Petter, Bondar, Irina, Chen, Mimi, Choi, Jin-Ho, Clements, Mark A, Colomar, Javier Ricardo, Daniels, Mark, Deerochanawong, Chaicharn, Desai, Vivek S, Desmangles, Jean-Claude G, Dillon, Robert G, Dixit, Naznin M, Du, Hongwei, Edelen, Rachel, Espinoza Peralta, Diego, Felipe Gacioppo, María Verónica, Ferraz, Tania Maria Bulcão Lousada, Galkina, Galina, Gallagher, Mary Patricia, George, Minu, Gonzalez, Edgar, Gottschalk, Michael Everett, Guido, Giancarlo, Hassan, Amir Ali, Hershkovitz, Eli, Huerta-Saenz, Lina P, Hwang, Jin Soon, Ibarra Gomez, Jaime Orlando, Irizarry Gonzalez, Lydia, Jain, Nina, Jelley, David H, Kim, Ho-Seong, Kovalenko, Tatiana, Laffel, Lori Michelle B, Leichter, Steven B, Liberatore Jr, Raphael Del Roio, Lynch, Jane, Mahmud, Farid Hussain, Malievskiy, Oleg Arturovich, Muir, Andrew, Nelson, Bryce A, Nevarez Ruiz, Luis Alejandro, Olson, Micah L, Pelayo Orozco, Emilia Susana, Peterkova, Valentina, Ramírez Mendoza, Fernando Ramón, Reddy, Konda Mohan, Rodriguez, Henry, Saenz, Javier Andres, Samoilova, Julia, Schwab, Karl-Otfried, Shah, Sejal H, Shehadeh, Naim, Shoemaker, Ashley H, Skorodok, Yulia, Sobolev, Aleksandr, Solís, Silvana Ernestina, Srinivasan, Shylaja, Tamborlane, William V, Tsalikian, Eva, Valeeva, Farida, Vance, Carl D, Velasquez-Mieyer, Pedro A, Violante Ortiz, Rafael Margarito, Votyakova, Olga, Wei, Haiyan, Weinstock, Ruth S, Wheeler, Mark D, Wicklow, Brandy Alexandra, Willi, Steven M, Wintergerst, Kupper A, Wolf, Risa M, Wood, Jamie Ruth, Yaliwal, Chandan, Yupanqui Lozno, Hernán |
| Zdroj: |
The Lancet Diabetes & Endocrinology; March 2023, Vol. 11 Issue: 3 p169-181, 13p |
| Abstrakt: |
The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
